PD-L1 blockade for urothelial carcinoma
Autor: | Josephine Kang, Lorenzo Galluzzi |
---|---|
Rok vydání: | 2017 |
Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine Oncology medicine.medical_specialty Durvalumab Immunology lcsh:RC254-282 Food and drug administration Avelumab 03 medical and health sciences 0302 clinical medicine Internal medicine PD-L1 medicine Immunology and Allergy Urothelial carcinoma biology business.industry lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Blockade Editorial 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Accelerated approval lcsh:RC581-607 business medicine.drug |
Zdroj: | OncoImmunology, Vol 6, Iss 7 (2017) |
ISSN: | 2162-402X |
Popis: | In May 2017, the US Food and Drug Administration (FDA) granted accelerated approval to durvalumab (IMFINZI®, from AstraZeneca UK Limited) and avelumab (BAVENCIO®, EMD Serono, Inc.) for use in patie... |
Databáze: | OpenAIRE |
Externí odkaz: |